Erika Florendo

972 total citations
17 papers, 121 citations indexed

About

Erika Florendo is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Erika Florendo has authored 17 papers receiving a total of 121 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 10 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Erika Florendo's work include Multiple Myeloma Research and Treatments (15 papers), CAR-T cell therapy research (7 papers) and Protein Degradation and Inhibitors (6 papers). Erika Florendo is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), CAR-T cell therapy research (7 papers) and Protein Degradation and Inhibitors (6 papers). Erika Florendo collaborates with scholars based in United States, Spain and Germany. Erika Florendo's co-authors include Samir Parekh, Sundar Jagannath, Hearn Jay Cho, Ajai Chari, Alessandro Laganà, Elaine Chan, Fevzi Yalniz, Jami Fukui, Vânia Hungria and Salomon Manier and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal of Cancer.

In The Last Decade

Erika Florendo

15 papers receiving 119 citations

Peers

Countries citing papers authored by Erika Florendo

Since Specialization

Citations

This map shows the geographic impact of Erika Florendo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erika Florendo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erika Florendo more than expected).

Fields of papers citing papers by Erika Florendo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erika Florendo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erika Florendo. The network helps show where Erika Florendo may publish in the future.

Co-authorship network of co-authors of Erika Florendo

This figure shows the co-authorship network connecting the top 25 collaborators of Erika Florendo. A scholar is included among the top collaborators of Erika Florendo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erika Florendo. Erika Florendo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	POSTER: MM-1070 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 Survival Subgroup Analyses 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Surbhi Sidana, Joaquín Martínez‐López, (unknown), Albert Oriol, Andrew Spencer, Binod Dhakal, Yaël C. Cohen, Cyrille Touzeau, Dominik Dytfeld, Hermann Einsele, Jesús F. San Miguel, Salomon Manier, Diana Chen, Katherine Li, (unknown), Carolina Lonardi, Arnab Ghosh, Nitin Patel, Erika Florendo, Simon J. Harrison	0
2	Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses. 2025 ·Journal of Clinical Oncology ·Surbhi Sidana, Joaquín Martínez‐López, Abdullah Khan, Albert Oriol, Andrew Spencer, Binod Dhakal, Yaël C. Cohen, Cyrille Touzeau, Dominik Dytfeld, Hermann Einsele, Jesús F. San Miguel, Salomon Manier, Ying Chen, Katherine Li, (unknown), Carolina Lonardi, Arnab Ghosh, Nitin Patel, Erika Florendo, Simon J. Harrison	1
3	Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis. 2024 ·Journal of Clinical Oncology ·Luciano J. Costa, Katja Weisel, (unknown), Surbhi Sidana, Yaël C. Cohen, Duncan Purtill, Cyrille Touzeau, Carlos Fernández de Larrea, Joaquín Martínez‐López, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, (unknown), Katherine Li, Martin Vogel, Mythili Koneru, Nitin Patel, Erika Florendo, (unknown), María‐Victoria Mateos	2
4	MM-549 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Luciano J. Costa, Katja Weisel, (unknown), Surbhi Sidana, Yaël C. Cohen, Duncan Purtill, Cyrille Touzeau, Carlos Fernández de Larrea, Joaquín Martínez‐López, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, (unknown), Katherine Li, Martin Vogel, Mythili Koneru, Nitin Patel, Erika Florendo, (unknown), (unknown)	0
5	Efficacy of Carvykti in Cartitude-4 Versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma 2024 ·Blood ·Michel Delforge, (unknown), María‐Victoria Mateos, Kristina Carlson, Keqin Qi, J. Mendes, (unknown), Jordan M. Schecter, William Deraedt, Carolina Lonardi, Ana Slaughter, Diana Chen, (unknown), (unknown), Nitin Patel, Erika Florendo, Hermann Einsele, Binod Dhakal, Wilfried Roeloffzen	3
6	Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials 2024 ·European Journal of Cancer ·Kwee Yong, Hermann Einsele, Jordan M. Schecter, Tito Roccia, William Deraedt, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, (unknown), Keqin Qi, Anil Londhe, Richard G. Carson, (unknown), (unknown), Satish Valluri, J. Mendes, Lida Pacaud, Nitin Patel, Erika Florendo, Binod Dhakal	2
7	Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Luciano J. Costa, Katja Weisel, (unknown), Surbhi Sidana, Yaël C. Cohen, Duncan Purtill, Cyrille Touzeau, Carlos Fernández de Larrea, Joaquín Martínez‐López, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, (unknown), Katherine Li, Martin Vogel, Mythili Koneru, Nitin Patel, Erika Florendo, (unknown), María‐Victoria Mateos	1
8	Nursing Care Throughout the Chimeric Antigen Receptor T-Cell Therapy Process for Multiple Myeloma 2023 ·Seminars in Oncology Nursing ·(unknown), (unknown), Erika Florendo, Erin Lee, (unknown), (unknown), (unknown)	3
9	Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Ajai Chari, Erika Florendo, (unknown), (unknown), Deepu Madduri, Samir Parekh, (unknown), (unknown), (unknown), (unknown), Alessandro Laganà, Sherry Bhalla, Sundar Jagannath	5
10	Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5) 2021 ·Blood ·Dominik Dytfeld, Binod Dhakal, Mounzer Agha, Salomon Manier, Michel Delforge, (unknown), (unknown), William Deraedt, (unknown), Jordan M. Schecter, (unknown), Fevzi Yalniz, Erika Florendo, Lida Pacaud, Vânia Hungria, Saad Z. Usmani, María‐Victoria Mateos	26
11	Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma 2021 ·Blood ·(unknown), (unknown), (unknown), Erika Florendo, (unknown), (unknown), (unknown), Juliet Escalon, (unknown), (unknown), Angela L. Lamb, Diana N. Kirke, Aimee L. Lucas, Sundar Jagannath, Hearn Jay Cho, Samir Parekh, Joshua Richter, Larysa Sanchez, Ajai Chari	13
12	A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma 2017 ·Blood Advances ·Ajai Chari, Hearn Jay Cho, (unknown), Gareth J. Morgan, (unknown), (unknown), (unknown), Erika Florendo, (unknown), (unknown), Elaine Chan, Violetta V. Leshchenko, Alessandro Laganà, Deepak Perumal, (unknown), Kaity Tung, Jami Fukui, Sundar Jagannath, Samir Parekh	45
13	Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma 2016 ·Blood ·Keren Osman, Ajai Chari, Samir Parekh, (unknown), Gillian Morgan, Erika Florendo, Elaine Chan, (unknown), (unknown), (unknown), John Mandeli, (unknown), Sundar Jagannath, Hearn Jay Cho	1
14	A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma 2016 ·Blood ·Ajai Chari, Hearn Jay Cho, Samir Parekh, K. H. Vincent Lau, Gillian Morgan, (unknown), (unknown), Meredith Curtis, Juliet Escalon, Erika Florendo, (unknown), (unknown), Elaine Chan, (unknown), (unknown), (unknown), (unknown), Sundar Jagannath	4
15	Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab 2015 ·Blood ·Ajai Chari, (unknown), (unknown), Sundar Jagannath, Hearn Jay Cho, Samir Parekh, K. H. Vincent Lau, Gillian Morgan, (unknown), Juliet Escalon, Erika Florendo, (unknown), Parul Doshi, Huaibao Feng, Clarissa Uhlar, Imran Khan, Tahamtan Ahmadi, Peter M. Voorhees, María‐Victoria Mateos, Suzanne Arinsburg	5
16	Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib 2015 ·Blood ·Ajai Chari, Hearn Jay Cho, Samir Parekh, Keren Osman, (unknown), Gillian Morgan, (unknown), (unknown), (unknown), Juliet Escalon, (unknown), Erika Florendo, (unknown), (unknown), (unknown), Elaine Chan, Sundar Jagannath	1
17	A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC). 2013 ·Journal of Clinical Oncology ·Allyson J. Ocean, Tanios Bekaii‐Saab, Imran Chaudhary, (unknown), Paul J. Christos, (unknown), Erika Florendo, (unknown), Joseph T. Ruggiero, E Popa, Melissa L. Wilson, Mohammad H. Ghalib, (unknown), Umang Shah, Lakshmi Rajdev, (unknown), George M. Gill, Matthew Coffey, Manish A. Shah, Sanjay Goel	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact